Podcast/Video Interviews by Stephen Ibaraki

A Chat with Michael Langer: Co-Founder and Managing Partner of T.Rx Capital; former Head of Search, Evaluation & In-licensing at Pear Therapeutics; Active in non-profit organizations: serves on the Leadership Board at Beth Israel Deaconess Medical Center, the Global Board of Directors for MassChallenge, the Leadership Board at the Terasaki Institute for Biomedical Innovation, is Senior Advisor of Special Projects at the Galenus Foundation

This week, Stephen Ibaraki has an exclusive interview with Michael Langer.

Michael Langer is the Co-Founder and Managing Partner of T.Rx Capital which is a fund specializing in investments in the creation, seed and Series A at the intersection of biology & technology. The fund is still in stealth mode and more will be revealed when launched publicly.

Michael is also active on the non-profit side. He serves on the Leadership Board at Beth Israel Deaconess Medical Center, the Global Board of Directors for MassChallenge, the Leadership Board at the Terasaki Institute for Biomedical Innovation and is the Senior Advisor of Special Projects at the Galenus Foundation. He previously co-founded the Young Coder's Society which teaches children how to code using Raspberry Pi's, served on the Board of Advisors at the Museum of Science and he was formerly a Young Leader at the Milken Institute and a World Economic Forum Global Shaper.

Michael previously founded Old Silver VC which is a family investment firm that invests in startups in Healthcare and Deep Tech with a focus on materials. They invested in 20+ companies including Big Hat Biosciences, Sesame Care, Seismic Therapeutics, Alto Pharmacy and Opentrons. Also involved were Susan Langer who is the former head of strategy at Biogen/current BOD member and Dr. Bob Langer who is an MIT Professor and founder of over 40 biotech companies including Moderna.

Michael was formerly Head of Search, Evaluation & In-licensing at Pear Therapeutics. During his time at Pear, Michael led or co-led 15 different transactions. Pear Therapeutics discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.

Michael previously spent time at several startups/venture capital funds including: Akili Interactive Labs, Udacity, Modern Meadow, Polaris Partners and Boston Seed Capital.

Michael has a BA from Lehigh University in Science, Technology and Society with a Double Minor in Entrepreneurship and Sustainable Development.